# Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer

> **NCT00124527** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 35 (—)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** Irofulven + capecitabine

## Key facts

- **NCT ID:** NCT00124527
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03-31
- **Primary completion:** 2006-08-31
- **Final completion:** 2006-08-31
- **Target enrollment:** 35 (—)
- **Last updated:** 2021-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00124527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00124527, "Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00124527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*